The intravascular stent is characterised in that the cut-outs (1) forming the segmented patterns of the stent construction at the same time form the elongated lines (2) of the main segment (3) situated around the longitudinal stent axis (4) and are connected via U-shaped connecting elements (5) thus creating around the longitudinal axis (4) of the stent a geometric pattern resembling a meander of gentle edges, and the two curves (6) in the shape of a sickle or the Latin letter "V" with rounded edges together with the oval plate (8) form a connecting segment (7) to connect with the connecting elements (5) of the elongated lines (2) of the main segment (3), wherein every next main segment (9) is a mirror reflection of the previous segment (10) and in that the curves (6) of the connecting element (7) in the shape of a sickle or the Latin letter "V" with rounded edges (6) are a mutual mirror reflection in relation to the oval plate (8) of the connecting segment (7). The extreme stent segments are the extreme main segments (12), whose every second outer connecting element (5) to connect the elongated lines (2) terminates in gentle passageways (13) with a plate in the shape of a round-point spade (14). The outer covering (15) of the stent comprises drugs, and in particular the drugs inhibiting cellular proliferation, and forms the layer covering the outer surface (16) of the stent. On the other hand, the inner covering accelerates the endothelialization of the stent construction and the re-endothelialization of the stent implantation site and comprises monoclonal anti-CD144 antibodies and a system of induction of tropomyosin-1 expression, especially covalent or electrostatic complexes of cell-penetrating peptides together with CRISPR/dCas9 system activating the tropomyosin-1 expression or with expression vectors determining the expression of human recombinant tropomyosin-1, or with stabilised mRNA molecules coding human tropomyosin-1.
